ethyl 1,2-dihydro-4-(3,4-dimethoxyphenyl)-6-methyl-2-oxopyrimidine-5-carboxylate | 893597-09-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: ethyl 1,2-dihydro-4-(3,4-dimethoxyphenyl)-6-methyl-2-oxopyrimidine-5-carboxylate
• 英文别名: ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1H-pyrimidine-5-carboxylate
• CAS: 893597-09-6
• 化学式: C₁₆H₁₈N₂O₅
• 分子量: 318.329
• InChiKey: SFVYAFMTYLADBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  86.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 1,2-dihydro-4-(3,4-dimethoxyphenyl)-6-methyl-2-oxopyrimidine-5-carboxylate 在 硝酸 、 三氯氧磷 作用下， 反应 1.08h， 生成 ethyl 2-chloro-4-(4,5-dimethoxy-2-nitrophenyl)-6-methylpyrimidine-5-carboxylate
  参考文献：
  名称：

  Molecular Design and Synthesis of Ivermectin Hybrids Targeting Hepatic and Erythrocytic Stages of Plasmodium Parasites

  摘要：

  Ivermectin is a powerful endectocide, which reduces the incidence of vector-borne diseases. Besides its strong insecticidal effect on mosquito vectors of the disease, ivermectin inhibits Plasmodium falciparum sporogonic and blood stage development and impairs Plasmodium berghei development inside hepatocytes, both in vitro and in vivo. Herein, we present the first report on structural modification of ivermectin to produce dual action molecular hybrids with good structure-dependent in vitro activity against both the hepatic and erythrocytic stages of P. berghei and P. falciparum infection, suggesting inclusion of ivermectin antimalarial hybrids in malaria control strategies. The most active hybrid displayed over threefold and 10-fold higher in vitro activity than ivermectin against hepatic and blood stage infections, respectively. Although an overwhelming insecticidal effect against Anopheles stephensi mosquitoes in laboratory conditions was not noticed, in silico docking analysis supports allosteric binding to glutamate-gated chloride channels similar to ivermectin.

  DOI：

  10.1021/acs.jmedchem.0c00033
• 作为产物：
  描述：

  ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one-5-carboxylate 在 硝酸 作用下， 反应 2.5h， 生成 ethyl 1,2-dihydro-4-(3,4-dimethoxyphenyl)-6-methyl-2-oxopyrimidine-5-carboxylate
  参考文献：
  名称：

  发现新的苯基磺酰基-嘧啶羧酸盐衍生物作为具有有效抗阿尔茨海默氏病作用的潜在多靶点药物：设计，合成，晶体结构和体外生物学评估

  摘要：

  阿尔茨海默氏病（AD）是行为和认知功能受损的多因素，进行性神经变性。多靶标配体（MTDL）策略在药物开发中是有前途的范例，可能为复杂的AD带来新的治疗选择。本文中，设计并合成了一系列新颖的MTDLs苯磺酰基-嘧啶羧酸酯（BS-1至BS-24）衍生物，用于AD治疗。所有合成的化合物均通过1 HNMR，13验证通过X射线单衍射分析对CNMR，HRMS和BS-19进行结构验证。为了评估设计的化合物的合理结合亲和力，进行了分子对接研究，结果表明它们与乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BuChE）的活性位点之间存在显着相互作用。合成的化合物在纳摩尔（nM）浓度下对AChE和BuChE表现出中等至出色的体外酶抑制活性。在24种化合物（BS-1至BS-24）中，最佳化合物（BS-10和BS-22）显示出对AChE的潜在抑制作用。IC 50  = 47.33±0.02 nM和51.36±0.04 nM，对BuChE有中等抑制作用；IC

  DOI：

  10.1016/j.ejmech.2021.113224

文献信息

• A novel combination of (diacetoxyiodo)benzene and tert-butylhydroperoxide for the facile oxidative dehydrogenation of 3,4-dihydropyrimidin-2(1H)-ones
  作者：Nandkishor N. Karade、Sumit V. Gampawar、Jeevan M. Kondre、Girdharilal B. Tiwari

  DOI：10.1016/j.tetlet.2008.09.045

  日期：2008.11

  A clean and efficient oxidative dehydrogenation of 3,4-dihydropyrimidin-2(1H)-ones to 1,2-dihydropyrimidines has been achieved through a novel combination of (diacetoxyiodo)benzene and tert-butylhydroperoxide in CH2Cl2.

  通过在CH 2 Cl 2中将（diacetoxyiodo ）苯和叔丁基氢过氧化物进行新颖的结合，已实现了3,4-dihydropyrimidin-2（1 H）-ones的干净高效氧化脱氢成1,2-dihydropyrimidines 。
• Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies
  作者：Manikanta Murahari、Karanam Vanitha Prakash、Godefridus J. Peters、YC Mayur

  DOI：10.1016/j.ejmech.2017.08.023

  日期：2017.10

  have identified 11a, 11b, 11d and 11h as potential inhibitors. Molecular docking studies identified the orientation and binding interactions at the active site of Akt1 and DNA. Compounds 12e and 12f have shown good cytotoxicity profile against lung cancer cell lines of sensitive and resistant type. Acute toxicity study of compound 12f at the dose of 5000 mg/kg has identified no signs of clinical toxicity

  设计具有取代的嘧啶的a啶酮的杂化系统，其目的是发现靶向癌细胞中多种机制的下一代抗癌药。通过实验室中简便的方法合成了杂合化合物，并通过NMR和质谱方法进行了表征，并筛选了针对A549（肺癌），Hela（宫颈），MCF7（乳腺癌）和MDA-MB-231（乳腺癌）细胞的细胞毒性线。化合物对细胞增殖的评估可鉴定出活性化合物11b，11d和11h对抗MCF7，MDA-MB-231和A549细胞系。用CT-DNA进行进一步的吸收滴定和凝胶电泳确定，杂化分子部分通过DNA嵌入显示出抗癌活性。用Akt激酶进行的蛋白质印迹分析的其他结果还表明，杂合化合物具有抑制Akt激酶活性并诱导凋亡的能力，而ABCC1则表明活性化合物也具有调节与ABCC1 / MRP1相关的多药耐药性（MDR）的能力。选择性Akt1激酶测定已确定11a，11b，11d和11h为潜在抑制剂。分子对接研究确定了Akt1和DNA活性位点的方向
• Free-radical oxidation of 1,2,3,4-tetrahydro-2-oxopyrimidines
  作者：Hamid Reza Memarian、Nazanin Jafarpour、Asadallah Farhadi

  DOI：10.1007/s00706-011-0573-8

  日期：2012.2

  Free-radical oxidation of 4-substituted 5-acetyl- and 5-carboethoxy-1,2,3,4-tetrahydro-2-oxopyrimidines using benzoyl peroxide under thermal conditions has been investigated to elucidate the effects of the nature of the substituents in the 4- and 5-positions on the rate of reaction. Whereas the presence of the acetyl group instead of the carboethoxy group in position 5 decreases the rate of oxidation, the nature of the additional substituent (electron-releasing or electron-withdrawing group) and also its location on the phenyl ring attached to C-4 of the tetrahydropyrimidinone ring effectively influence the rate of reaction. The latter observation supports the proposal that the removal of the 4-hydrogen on the heterocyclic ring occurs in the rate-determining step.
• Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer’s action: Design, synthesis, crystal structure and in-vitro biological evaluation
  作者：Shoaib Manzoor、Santosh Kumar Prajapati、Shreyasi Majumdar、Md Kausar Raza、Moustafa T. Gabr、Shivani Kumar、Kavita Pal、Haroon Rashid、Suresh Kumar、Sairam Krishnamurthy、Nasimul Hoda

  DOI：10.1016/j.ejmech.2021.113224

  日期：2021.4

  BS-22) displayed potential inhibition against AChE; IC50 = 47.33 ± 0.02 nM and 51.36 ± 0.04 nM and moderate inhibition against BuChE; IC50 = 159.43 ± 0.72 nM and 153.3 ± 0.74 nM respectively. In the enzyme kinetics study, the compound BS-10 displayed non-competitive inhibition of AChE with Ki = 8 nM. Respective compounds BS-10 and BS-22 inhibited AChE-induced Aβ1-42 aggregation in thioflavin T-assay at

  阿尔茨海默氏病（AD）是行为和认知功能受损的多因素，进行性神经变性。多靶标配体（MTDL）策略在药物开发中是有前途的范例，可能为复杂的AD带来新的治疗选择。本文中，设计并合成了一系列新颖的MTDLs苯磺酰基-嘧啶羧酸酯（BS-1至BS-24）衍生物，用于AD治疗。所有合成的化合物均通过1 HNMR，13验证通过X射线单衍射分析对CNMR，HRMS和BS-19进行结构验证。为了评估设计的化合物的合理结合亲和力，进行了分子对接研究，结果表明它们与乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BuChE）的活性位点之间存在显着相互作用。合成的化合物在纳摩尔（nM）浓度下对AChE和BuChE表现出中等至出色的体外酶抑制活性。在24种化合物（BS-1至BS-24）中，最佳化合物（BS-10和BS-22）显示出对AChE的潜在抑制作用。IC 50  = 47.33±0.02 nM和51.36±0.04 nM，对BuChE有中等抑制作用；IC
• Molecular Design and Synthesis of Ivermectin Hybrids Targeting Hepatic and Erythrocytic Stages of <i>Plasmodium</i> Parasites
  作者：Lovepreet Singh、Diana Fontinha、Denise Francisco、Antonio M. Mendes、Miguel Prudêncio、Kamaljit Singh

  DOI：10.1021/acs.jmedchem.0c00033

  日期：2020.2.27

  Ivermectin is a powerful endectocide, which reduces the incidence of vector-borne diseases. Besides its strong insecticidal effect on mosquito vectors of the disease, ivermectin inhibits Plasmodium falciparum sporogonic and blood stage development and impairs Plasmodium berghei development inside hepatocytes, both in vitro and in vivo. Herein, we present the first report on structural modification of ivermectin to produce dual action molecular hybrids with good structure-dependent in vitro activity against both the hepatic and erythrocytic stages of P. berghei and P. falciparum infection, suggesting inclusion of ivermectin antimalarial hybrids in malaria control strategies. The most active hybrid displayed over threefold and 10-fold higher in vitro activity than ivermectin against hepatic and blood stage infections, respectively. Although an overwhelming insecticidal effect against Anopheles stephensi mosquitoes in laboratory conditions was not noticed, in silico docking analysis supports allosteric binding to glutamate-gated chloride channels similar to ivermectin.